

78474\_Auto\_Edited.docx

**Inflammatory myofibroblastic tumor of central nervous system: A Case Report and Literature Review**

IMT of CNS

Zhenjin Su, Zeshang Guo, Hengtong Wan, Xinyu Hong

**Abstract****BACKGROUND**

An inflammatory myofibroblastic tumor (IMT) occurring in the central nervous system (IMT-CNS) is very rare, and thus, its pathogenesis is unknown. This case report and literature review aimed to explore the pathogenesis, clinical features, imaging findings, pathological characteristics, immunohistochemical characteristics, diagnoses, treatments, and risks of postoperative recurrence of IMT-CNS.

**CASE SUMMARY**

A 67-year-old woman was admitted to the hospital with an exophthalmic protrusion and double vision in the left eye that had persisted for 3 mo. Magnetic resonance imaging (MRI) showed a 2.4×1.3-cm heterogeneous large mass in the bottom of the left anterior cranial fossa, which was closely related to the dura mater. Before surgery, we suspected the mass to be meningioma. The entire mass was successfully removed under neuronavigation and electrophysiological monitoring, and postoperative pathology indicated an IMT with extensive infiltration of chronic inflammatory cells and scattered multinucleated giant cells. Head MRI at the 3-month follow-up showed that the tumor

at the bottom of left anterior cranial fossa had been completely resected without recurrence.

## CONCLUSION

From the histological, immunohistochemical, and genetic analyses, the present case suggests that the pathogenesis of IMT-CNS is related to autoimmunity.

**Key Words:** Inflammatory myofibroblastic tumor; central nervous system; pathogeny; diagnosis; treatment; risk of postoperative recurrence

Su Z, Guo Z, Wan H, Hong X. Inflammatory myofibroblastic tumor of central nervous system: A Case Report and Literature Review. *World J Clin Cases* 2022; In press

**Core Tip:** Inflammatory myofibroblastic tumor of central nervous system

## INTRODUCTION

Inflammatory myofibroblastic tumors (IMTs) are characterized by proliferation of myofibroblastic spindle cells with mixed inflammatory infiltrates of plasma cells, lymphocytes, eosinophils, and histiocytes. While the most common site for these tumors is the lung in the form of a plasma cell granuloma, IMTs can occur in nearly every organ system, including the lung, liver, mesenteric system, gastrointestinal tract, retroperitoneum, urinary bladder, upper respiratory tract, and mediastinum. However, an IMT of the central nervous system (IMT-CNS) is an extremely rare disease (1,2). IMTs were once referred to with diverse names such as inflammatory pseudotumor (IPT), plasma cell granuloma, pseudosarcomatous myofibroblastic proliferation, and inflammatory myofibrohistiocytic proliferation (7,10,14). Then in the 2002 World Health Organization (WHO) classification of soft tissue tumors, these lesions were renamed “inflammatory myofibroblastic tumors” and allocated to the soft tissue tumor category. When the WHO revised the classification of soft tissue tumors in 2003 and again 2020,

no changes were made regarding IMTs. However, in the latest 2021 WHO classification of CNS tumors, the content related to IMTs was revised to be consistent with that of soft tissue tumors. Recent studies have shown that nearly 50% of IMTs have clonal rearrangements of the anaplastic lymphoma kinase (ALK) receptor tyrosine kinase gene located on 2p23 and show immunohistochemical expression of ALK protein (3).

Herein, we present a case in which an IMT was found in the bottom left anterior cranial fossa. To better understand the pathological and radiological features of IMT-CNS as well as the relevant surgical treatment, adjuvant therapy, prognosis, and important different diagnoses, we also reviewed 49 cases of IMT-CNS reported in the literature since the year 2000.

## **CASE PRESENTATION**

### ***Chief complaints***

A 67-year-old woman was admitted to the hospital for an exophthalmic protrusion and double vision in the left eye persisting for 3 mo.

### ***History of present illness***

The patient's symptoms had started 3 mo previously with an exophthalmic protrusion and double vision in the left eye.

### ***History of past illness***

The patient had no notable medical history.

### ***Personal and family history***

The patient had no notable personal and family history.

### ***Physical examination***

On physical examination, the patient had a temperature of 36.6 °C, heart rate of 93 bpm, respiratory rate of 16 breaths per min, blood pressure of 180/90 mmHg, and oxygen

saturation in room air of 98%. The physical examination showed a fixed left eyeball, without any other pathological signs.

### *Laboratory examinations*

The preoperative complete blood count and coagulation results were all within normal ranges. Postoperative blood analysis revealed mild leukocytosis based on a leukocyte count of  $11 \times 10^9/L$  with predominantly neutrophils, a mildly reduced hemoglobin level of 113 g/L, a markedly elevated C-reactive protein level of 180 mg/dL, and a normal procalcitonin level of 0.056 ng/mL. The erythrocyte sedimentation rate was also normal. Arterial blood gas analysis showed mild lactic acid accumulation and metabolic acidosis. Other test results including blood glucose, urine analysis, stool analysis and coagulation were all within normal ranges.

### *Imaging examinations*

Computed tomography (CT) showed a hypointense mass in the bottom of the left anterior cranial fossa with a CT value of 45 HU. Magnetic resonance imaging (MRI) showed a large oval mass measuring 2.4×1.3 cm in the bottom of the left middle cranial fossa, with slight hyperintense signals on T1-weighted imaging (T1WI) and slightly hypointense signals on T2-weighted imaging (T2WI) (Figure 1A-B). Isointense signal was observed on the fluid attenuated inversion recovery (FLAIR) image (Figure 1C). After gadolinium administration, obvious heterogenous enhancement was observed (Figure 1D). MRI showed significant compression displacement of the left optic nerve. No obvious restriction was observed on diffusion weighted imaging (DWI).

## **LABORATORY EXAMINATIONS**

The preoperative complete blood count and coagulation results were all within normal ranges. Postoperative blood analysis revealed mild leukocytosis based on a leukocyte count of  $11 \times 10^9/L$  with predominantly neutrophils, a mildly reduced hemoglobin level of 113 g/L, a markedly elevated C-reactive protein level of 180 mg/dL, and a

normal procalcitonin level of 0.056 ng/mL. The erythrocyte sedimentation rate was also normal. Arterial blood gas analysis showed mild lactic acid accumulation and metabolic acidosis. Other test results including blood glucose, urine analysis, stool analysis and coagulation were all within normal ranges.

1

### **PHYSICAL EXAMINATION**

On physical examination, the patient had a temperature of 36.6 °C, heart rate of 93 bpm, respiratory rate of 16 breaths per min, blood pressure of 180/90 mmHg, and oxygen saturation in room air of 98%. The physical examination showed a fixed left eyeball, without any other pathological signs.

### **FINAL DIAGNOSIS**

The results of pathological examination were suggestive of IMT. Hematoxylin and eosin-stained paraffin sections predominantly showed an IMT with extensive infiltration of chronic inflammatory cells and scattered multinucleated giant cells (Figure 2A, B). Immunohistochemical analysis indicated that the tumor was negative for ALK expression (Figure 2C). However, the specimen was positive for Exponential Moving Average (EMA, Figure 2D), immunoglobulin G4 (IgG4, Figure 2E), vimentin (Figure 2F), smooth muscle actin (SMA), cluster of differentiation 20 (CD20), and B-cell lymphoma-2 (Bcl-2) as well as negative for S-100, progesterone receptor (PR), and somatostatin receptor (SSTR2). In addition, *in situ* hybridization showed negative results for Epstein Barr virus (EBV)-encoded RNA (EBER).

### **TREATMENT**

7

A preoperative clinical and radiological diagnosis of meningioma was made, and surgery was performed with preoperative neuronavigation and intraoperative neurophysiological monitoring. The tumor was located at the base of the anterior cranial fossa 3.5 cm away from the bone window. The tumor appeared kermesinus and tough with a clear boundary from the surrounding tissues. The basal part was adhered

tightly to the base of the anterior cranial fossa and sellar tubercle. The tumor filled the entire left wing of the sphenoid bone and completely wrapped around the pituitary stalk, left optic nerve, left internal carotid artery, and left posterior communicating artery. The tumor was pushing the left oculomotor nerve outward. The tumor blood supply decreased significantly after the tumor base was severed. During surgery, the tumor was completely removed. The patient then developed oculomotor nerve palsy after surgery. Hence, we suspected an oculomotor schwannoma. Postoperative CT (Figure 1E) showed that the lesion was completely resected, with no signs of residual tumor.

### **OUTCOME AND FOLLOW-UP**

This patient was followed up at 3 mo after surgery. Head MRI showed that the tumor at the bottom of left anterior cranial fossa had been completely resected without recurrence (Figure 1F). As the tumor was completely wrapped around the left optic nerve before surgery, the nerve was inevitably injured during surgery. On general medical examination, the vision of the left eye had improved to a level only slightly lower than that pre-operation. The function of the left abducens nerve had recovered. In addition, headache and ophthalmalgia were completely resolved.

### **DISCUSSION**

IMT in the CNS, as observed in the present case, is very rare. For the purpose of characterizing the features of this disease, we performed a literature review of IMT-CNS cases. We recorded and analyzed the data for all cases that met the inclusion criteria of ALK immunohistochemical staining and treatment involving surgical resection since 2000 based on the timing of the WHO definition. After reviewing the literature related to IMT, we recorded the relevant data for 49 cases, which are presented in Table 1 in reverse chronological order.

Among the 49 cases, 27 cases (55.1%) were treated by simple complete resection of the mass, 5 cases (10.2%) by simple partial resection of the mass, and the other 17 cases



(34.7%) with comprehensive treatment. We found that the method of resection did not affect the recurrence of IMT ( $P = 0.521$ ; Table 1). Postoperative immunohistochemical results showed that a total of 10 cases (20.4%) were ALK positive. A total of 9 cases (18.4%) experience recurrence within 5 years after comprehensive treatment (Table 2). We observed that positive ALK expression in IMTs was associated with a higher recurrence rate (6/10) than negative ALK expression (1/14;  $P = 0.009$ ).

### *Epidemiology*

IMT is a type of mesenchymal neoplasm, which frequently occurs in the lung (14,17). IMT most commonly affects children and young adults, with a median age at first onset of 36 years (14). The youngest reported age at onset is 3 mo (18) (age range: 3 mo to 82 years). Among the 49 cases reviewed, the mean patient age at onset was 41.0 years (range: 7–82 years), and there were 24 male and 25 female patients. Among these patients, the presenting sites were the hemicerebrum ( $n = 26$ ), cerebellum ( $n = 3$ ), basis cranii ( $n = 6$ ), ventricle ( $n = 5$ ), cavernous sinus ( $n = 3$ ), and other CNS sites ( $n = 6$ ; Table 1). By comparison, our patient was a 67-year-old woman who had an IMT in the bottom of the left anterior cranial fossa, and thus, this case was extremely rare.

### *Pathogenesis*

The exact pathogenesis of IMT remains unclear to date. Some authors have suggested that the disease is related to bacterial and viral infections such as EBV and human herpesvirus (3,8,12). However, EBV and human herpesviruses type 8 (HHV-8) were negative in the majority of cases. In the report by Häusler *et al.*, polymerase chain reaction (PCR) analysis of the patient's cerebrospinal fluid (CSF) proved negative for *Mycobacteria*, herpes simplex virus, varicella-zoster virus, JC polyoma virus (JC virus), EBV, HHV-6, and HHV-8 (4). The majority of our reviewed cases also showed no viral infection. However, these negative findings do not rule out a viral etiology, as it is possible the viral load may have been too low, viruses not being specifically investigated may be involved, and viruses may have triggered inflammatory or even



neoplastic processes before being eliminated from the brain tissue (4,5,9). Some patients had pulmonary nodules prior to the discovery of intracranial space-occupying lesions, and we believe that the occurrence of IMT may be associated with such lesions (10). Because some researchers discovered polyclonal hypergammaglobulinemia, hyperleukocytosis, and an increased sedimentation rate in some cases, it is also believed that IMT is an immune-related disorder (6,9,12). Accordingly, corticosteroids have been used in IMT treatment. Post-traumatic or post-surgical mechanisms have also been proposed without convincing evidence (9,12).

### *Clinical manifestations*

Primary intracranial IMT is associated with a variety of clinical manifestations, mainly related to tumor location, size, relationship with surrounding tissues, and degree of edema. In the cases we reviewed, clinical symptoms included headache ( $n = 6$ , 35.3%), blurred vision ( $n = 5$ , 29.4%), ptosis ( $n = 2$ , 11.8%), seizure ( $n = 2$ , 11.8%), attention deficiency ( $n = 1$ , 5.9%), diplopia ( $n = 1$ , 5.9%), and dizziness ( $n = 1$ , 5.8%). The average duration of clinical symptoms was 2.7 mo (range, 9 days to 6 mo). The duration of the clinical presentation in our patient matched that reported in the literature. Unusual clinical signs including polyclonal hypergammaglobulinemia, hyperleukocytosis, and increased sedimentation rate have been reported in some studies (12). Hence, it is advisable to screen for these during clinical evaluation. In our case report, the patient's major complaint was exophthalmic protrusion and double vision, suggesting a mass in the bottom left middle cranial fossa.

### *Imaging features*

After reviewing the previous literature, we found that IMT-CNS presents diverse results on T1WI, with most presenting isointense or hyperintense signals in T2WI (1,6,7,9,12,14,16). <sup>5</sup> The relative hypointensity of these lesions on T2WI, as seen in our case, can probably be attributed to the decreased free water content and is associated with a lack of mobile protons relative to a high degree of fibrosis and an elevated

cellularity or high nucleus-to-cytoplasm ratio (22,23). In most of the reviewed cases, heterogenous enhancement was observed after gadolinium administration. Our patient's findings were consistent with the abovementioned findings. According to Haulser *et al* (3), the anatomical location is highly variable, with meningeal lesions being the most frequently encountered type (4). Some authors believe that IMT originates in the dura mater (2,9). Lesions in ~28% of cases showed local thickening and/or radiologic enhancement of the dura mater (3,7,11), and this is consistent with our findings.

### Diagnosis

IMT can occur in virtually every organ system, but intracranial cases are extremely rare (1,8). There is no gold standard diagnostic marker yet for IMT, and diagnosis is currently mainly dependent on a combination of histological examination, immunohistochemical analysis, and molecular genetic analyses. In general, IMTs consist of a large number of myofibroblastic spindle cells with mixed inflammatory infiltrates of plasma cells, lymphocytes, eosinophils, multinuclear giant cells, and histiocytes (1,3,13,15). These cells co-exist in a collagen matrix with differing degrees of vascularization (4,8). Many other lesions such as lymphoplasmacyte-rich meningioma, schwannoma, lymphoma, and plasmacytoma have similar histological features as IMT. Lymphoma diagnosis can be ruled out by determining whether the cells are polyclonal. In addition, IMT is often closely associated with the dura, wherein the spindle cells are often mistaken for meningioma cells. This can be identified by concentric fibrosis in small vessels, which would not be present in meningioma (2,4,5). Immunohistochemical analysis is an extremely important means of diagnosis of IMT. Fluorescence *in situ* hybridization (FISH) with a probe flanking the *ALK* gene at 2p23 typically demonstrates a genetic rearrangement. While tumors with *ALK* gene rearrangements are readily considered a unique neoplastic category, histologically similar neoplastic lesions may lack this genetic alteration (3). *ALK* expression is positive in nearly 50% patients with IMT, especially in children, and is associated with local recurrence and distant

metastasis (17). However, in the literature we reviewed, only about 25% cases were positive for ALK expression. All other immunohistochemical markers are equally important. Spindle cells have the immunohistochemical characteristics of myofibroblasts and often express vimentin and SMA (5). Meningioma also shows infiltration by fibrous ground tissue and mononuclear cells, but the finding of meningeal whorls and positive EMA were not observed in IMT-CNS (4). S-100 is used to differentiate Rosai-Dorfman disease. In recent years, IgG4 and programmed death receptor-1 (PD-1) have been proposed as markers to assist the diagnosis and treatment of IMT. IgG4-associated IMT was first detected in masses at sites other than the CNS. Some are part of a systemic disorder known as IgG4-related sclerosing disease. We found that intracranial IMTs had similar characteristics with IgG4-associated IMTs, except for the absence of granulomas and reactive lymphatic follicles (2). Therefore, IgG4 may be useful for the diagnosis of IMT. Unfortunately, serum IgG4 Levels have not been measured for most reported cases to date. Cottrell *et al* recently studied the relationship between PD-L1 expression and IMT. They found that in IMT, PD-L1 is highly expressed in both tumor and immune cells, and that it was also commonly expressed in ALK (-) negative cases (88%), whereas adaptive PD-L1 expression was present in the majority of tumors (20). Our review of previous cases showed that immune-related mechanisms play an important role in the pathogenesis of IMT; thus, we should aim to detect the levels of relevant antibodies in the serum and CSF as well as measure the erythrocyte sedimentation rate and other laboratory indicators to assist in the diagnosis of IMT.

#### *Treatment strategy*

Due to the rarity of IMT-CNS, no gold standard therapy has yet been identified. Currently, complete surgical resection of the tumor is the preferred treatment. In addition to surgical treatment, several other treatment options have emerged in recent years. Many researchers have treated IMT with corticosteroids for autoimmune pathogenesis, and the clinical and radioimaging findings showed improvement in most

cases after such treatment (2,5,7,8). Radiation therapy is rarely used in the treatment of IMT, and its efficacy is uncertain (5). Several reportedly active regimens have been described in literature, including vincristine plus methotrexate, vincristine plus etoposide, cisplatin/carboplatin-based regimes, ifosfamide-based regimens, and doxorubicin in combination with other drugs and taxanes (24,25,26). Mycophenolate mofetil (MMF) is commonly used in the treatment of IgG4-related immune diseases, and Moss *et al* proposed the use of MMF in IgG4-positive IMT patients. In two cases, the side effects of corticosteroids were greatly improved after MMF treatment and clinical symptoms were relieved (6). In some cases, rituximab also helped shrink the IMT and improve the patient's symptoms (10). The exact mechanism of action of rituximab is unknown, but it is believed to induce apoptosis *via* complement and antibody-dependent cell-mediated cytotoxicity (19).

#### *Risk of postoperative recurrence*

Although IMT is a benign disease, the risk of recurrence is high (4). The histological features of the recurrent tumor have been consistent with IMT. However, the morphology of the recurrent tumor showed a more sarcomatous pattern (27). In this review, we sought to identify the high-risk factors related to IMT recurrence. We divided 47 cases of IMT-CNS into groups according to the resection method, ALK expression and gender, and counted the number of cases with tumor recurrence in each group. Seven patients treated with total tumor resection experienced recurrence within 5 years, and five patients with subtotal tumor resection experienced recurrence. Postoperative immunohistochemistry showed that only one ALK positive cases did not experienced recurrence within 5 years, while only one ALK negative case experienced recurrence within 5 years. We applied the Fisher exact probability method to analyze these data, using Statistical Product and Service Solutions software (SPSS 23.0, Chicago, IL, USA). We found that ALK expression had an effect on recurrence of IMT-CNS ( $P < 0.05$ ; Table 2).

The expression of some immunohistochemical factors is related to drug sensitivity, which affects disease prognosis (4,13). In general, gross total resection should be used as a surgical target. Interestingly, statistical analysis showed that the method of resection had no effect on the recurrence of IMT ( $P>0.05$ ; Table 3). We think this may be related to the fact that IMT is a low-grade aggressive tumor. However, we should still use total resection as the first option whenever possible. Immunohistochemistry and other data should be used to determine the follow-up treatment to reduce disease recurrence. Finally, we believe that as our understanding of IMT continues to grow, a prognosis based on the biological profile of tumors is possible.

## **CONCLUSION**

Intracranial IMT is a very rare disease. We summarized and analyzed 49 cases of intracranial IMT and found that the incidence rates in male and female patients were similar. Headache is the most common initial symptom in clinical manifestations, but it is also closely related to the location of tumor growth. MRI is an important means of IMT diagnosis, and expression of ALK, as an important molecular marker of IMT, has been widely used in recent years. Complete surgical resection of the tumor is the preferred treatment, and continued treatment after operation cannot be ignored. For tumors that are difficult to remove, glucocorticoids, radiotherapy and other treatments can be administered to limit tumor growth or even eliminate tumors. ALK expression was closely related to the recurrence of IMT. Further analyses of more cases of IMT-CNS and long-term follow-up investigations are needed. We believe our case report provides an additional reference for clinicians for the pathogenetic diagnosis and treatment of IMT-CNS.

14%

SIMILARITY INDEX

---

PRIMARY SOURCES

---

- |       |   |                |
|-------|---|----------------|
| 1     | <a href="http://www.wjgnet.com">www.wjgnet.com</a><br><small>Internet</small>   | 102 words — 3% |
| <hr/> |   |                |
| 2     | Rebecca S. Swain, Tarik Tihan, Andrew E. Horvai, Dolores Di Vizio et al. "Inflammatory myofibroblastic tumor of the central nervous system and its relationship to inflammatory pseudotumor", Human Pathology, 2008<br><small>Crossref</small>              | 62 words — 2%  |
| <hr/> |   |                |
| 3     | <a href="http://academic.oup.com">academic.oup.com</a><br><small>Internet</small>   | 60 words — 2%  |
| <hr/> |   |                |
| 4     | Martin Häusler, Lars Schaade, Vincent T. Ramaekers, Martin Doenges, Gerhard Heimann, Bernd Sellhaus. "Inflammatory pseudotumors of the central nervous system: Report of 3 cases and a literature review", Human Pathology, 2003<br><small>Crossref</small> | 41 words — 1%  |
| <hr/> |   |                |
| 5     | <a href="http://www.ajnr.org">www.ajnr.org</a><br><small>Internet</small>   | 40 words — 1%  |
| <hr/> |   |                |
| 6     | Philip C.W. Lui, Yuen Shan Fan, Steve S. Wong, Alice N.H. Chan et al. "Inflammatory pseudotumors of the central nervous system", Human Pathology, 2009<br><small>Crossref</small>   | 31 words — 1%  |
| <hr/> |   |                |
| 7     | <a href="http://www.ncbi.nlm.nih.gov">www.ncbi.nlm.nih.gov</a><br><small>Internet</small>   |                |



30 words — 1%

8 Francesca Favini, Antonio Giordano Resti, Paola Collini, Michela Casanova, Cristina Meazza, Giovanna Trecate, Andrea Ferrari. "Inflammatory myofibroblastic tumor of the conjunctiva: Response to chemotherapy with low-dose methotrexate and vinorelbine", *Pediatric Blood & Cancer*, 2010  
Crossref 29 words — 1%

9 Tian-Yi Wang, Bian-Li Wang, Fu-Rong Wang, Meng-Yuan Jing, Lu-Dan Zhang, De-Kui Zhang. "Thoracoscopic resection of a large lower esophageal schwannoma: A case report and review of the literature", *World Journal of Clinical Cases*, 2021  
Crossref 20 words — 1%

10 [www.birpublications.org](http://www.birpublications.org)  
Internet 16 words — < 1%

11 [f6publishing.blob.core.windows.net](http://f6publishing.blob.core.windows.net)  
Internet 14 words — < 1%

12 Sang Hoon Yoon. "Inflammatory myofibroblastic tumor in the intradural extramedullary space of the lumbar spine with spondylolisthesis: case report and review of the literature", *European Spine Journal*, 11/26/2009  
Crossref 13 words — < 1%

13 Xiao Zhou, Mei-Li Duan. "Malaria-associated secondary hemophagocytic lymphohistiocytosis: A case report", *World Journal of Clinical Cases*, 2021  
Crossref 13 words — < 1%

14 Ning Lin, Lissa Baird, McKenzie Koss, Kimberly E. Kopecky, Evelyne Gone, Nicole J. Ullrich, R. Michael Scott, Edward R. Smith. "Discovery of asymptomatic  
12 words — < 1%



moyamoya arteriopathy in pediatric syndromic populations: radiographic and clinical progression", Neurosurgical Focus, 2011

Crossref

15

P. Gerlero, Á. Hernández-Martín. "Treatment of Warts in Children: An Update", Actas Dermo-Sifiliográficas (English Edition), 2016

12 words — < 1%

Crossref

EXCLUDE QUOTES	ON	EXCLUDE SOURCES	< 12 WORDS
EXCLUDE BIBLIOGRAPHY	ON	EXCLUDE MATCHES	< 12 WORDS